Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | PNMT | P11086 | 2/20 | 0.50 |
| ▸ | ACHE | P22303 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29868670 | 1.00 | CHRM2 (0.65) | CHRM2CYP1A2CYP3A4CYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL28578179 | 0.98 | CHRM2 (0.62) | CHRM2CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL7066938 | 0.87 | CHRM2 (0.74) | CHRM2CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL5909429 | 0.85 | PARP1 (0.47) | CHRM2CYP1A2CYP2D6CYP2C19LMNA | |
| SCHEMBL21674322 | 0.85 | CHRM2 (0.71) | CHRM2CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL7774786 | 0.83 | CHRM2 (0.81) | CHRM2CYP1A2CYP3A4CYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL31169761 | 0.83 | CHRM2 (0.69) | CHRM2CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL13975775 | 0.82 | CHRM2 (0.77) | CHRM2CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL15110660 | 0.82 | CHRM2 (0.67) | CHRM2CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL13973164 | 0.81 | CYP19A1 (0.63) | CYP1A2CYP3A4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117447334-A | Method for efficiently synthesizing alpha-amino acetal | 南京工业大学 | 2024-01-26 | — | — | CN | claimed |
| CN-117447334-A | Method for efficiently synthesizing alpha-amino acetal | 南京工业大学 | 2024-01-26 | — | — | CN | disclosed |
| WO-2020247540-A1 | ADENOSINE ANALOGS FOR THE TREATMENT OF DISEASE | BIOINTERVENE, INC. (US) | 2020-12-10 | — | — | WO | disclosed |
| US-10093630-B2 | Pyrazole compounds and methods of making and using same | ABIDE THERAPEUTICS, INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-20180186808-A1 | NARGENICIN COMPOUNDS AND USES THEREOF AS ANTIBACTERIAL AGENTS | MERCK SHARP & DOHME LLC | 2018-07-05 | — | — | US | disclosed |
| US-9944654-B2 | Nargenicin compounds and uses thereof as antibacterial agents | MERCK SHARP & DOHME CORP. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20170305924-A1 | NARGENICIN COMPOUNDS AND USES THEREOF AS ANTIBACTERIAL AGENTS | MERCK SHARP & DOHME CORP. (US) | 2017-10-26 | — | — | US | disclosed |
| US-20170298090-A1 | Modulators of ROR-gamma Receptors, Composition and Use Thereof | KULING THERAPEUTICS (CN) | 2017-10-19 | — | — | US | disclosed |
| US-20170190669-A1 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2017-07-06 | — | — | US | disclosed |
| WO-2015179559-A2 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABIDE THERAPEUTICS, INC. (US) | 2015-11-26 | — | — | WO | disclosed |
| US-20110021513-A1 | MODULATORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE | BIOGEN IDEC MA INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-20100056516-A1 | 1-HYDROXY NAPHTHYRIDINE COMPOUNDS AS ANTI-HIV AGENTS | MERCK SHARP & DOHME CORP. | 2010-03-04 | — | — | US | disclosed |
| US-7482359-B2 | Androgen receptor modulators | MERCK & CO., INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-7354919-B2 | Isoxazole compositions useful as inhibitors of ERK | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-04-08 | — | — | US | disclosed |
| US-20070293511-A1 | Crf Receptor Antagonists and Methods | SB PHARMCO PUERTO RICO INC. AND NEUROCRINE BIOSCIENCES, INC., A CORPORATION | 2007-12-20 | — | — | US | disclosed |
| US-20070269405-A1 | Androgen Receptor Modulators | MERCK SHARP & DOHME CORP. | 2007-11-22 | — | — | US | disclosed |
| WO-2005095343-A1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2005-10-13 | — | — | WO | disclosed |
| CN-1376155-A | Thiourea and isothiourea derivatives for inhibiting RAS-transformed cell growth | YUHAN CORP (KR) | 2002-10-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190669-A1 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABHD6, FAAH, FAAH2 | CHRM2 4682/4885CYP1A2 1412/4885CYP3A4 976/4885 |
| US-20180186808-A1 | NARGENICIN COMPOUNDS AND USES THEREOF AS ANTIBACTERIAL AGENTS | NRDC, MME, NME2 | CHRM2 4591/4885CYP1A2 1840/4885CYP3A4 2199/4885 |
| US-20070293511-A1 | Crf Receptor Antagonists and Methods | CRHR1, CRHR2, CRH | CHRM2 378/4885CYP1A2 977/4885CYP3A4 1101/4885 |
| US-20170305924-A1 | NARGENICIN COMPOUNDS AND USES THEREOF AS ANTIBACTERIAL AGENTS | NRDC, MME, NME2 | CHRM2 4591/4885CYP1A2 1840/4885CYP3A4 2199/4885 |
| US-20110021513-A1 | MODULATORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE | IRAK1, IRAK2, IRAK3 | CHRM2 4316/4885CYP1A2 4611/4885CYP3A4 4694/4885 |
| US-20070269405-A1 | Androgen Receptor Modulators | AR, SHBG, FSHR | CHRM2 803/4885CYP1A2 972/4885CYP3A4 2087/4885 |
| US-20100056516-A1 | 1-HYDROXY NAPHTHYRIDINE COMPOUNDS AS ANTI-HIV AGENTS | RNASEH1, RNASE1, RNASEL | CHRM2 3822/4885CYP1A2 896/4885CYP3A4 857/4885 |
| US-10093630-B2 | Pyrazole compounds and methods of making and using same | ABHD6, FAAH, FAAH2 | CHRM2 4682/4885CYP1A2 1412/4885CYP3A4 976/4885 |
| US-20170298090-A1 | Modulators of ROR-gamma Receptors, Composition and Use Thereof | RORC, RORB, RORA | CHRM2 1088/4885CYP1A2 1954/4885CYP3A4 3368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.